about
Evolutionary Limitation and Opportunities for Developing tRNA Synthetase Inhibitors with 5-Binding-Mode ClassificationAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsProliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithineThe Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.Attacking the supply wagons to starve cancer cells to death.Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways.Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.Molecular basis and current strategies of therapeutic arginine depletion for cancer.Arginine dependence of tumor cells: targeting a chink in cancer's armor.Arginine Metabolism Revisited.Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer modelsMetabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.Arginase 1 promotes retinal neurovascular protection from ischemia through suppression of macrophage inflammatory responses
P2860
Q26775728-15C14345-4E17-4C9D-9EB4-79A70AAB9DDAQ30040775-7943694B-5FA8-4247-897E-3273485525D9Q33598120-C76E1646-0C3B-4226-B812-6DC8018910BAQ33838601-EE834229-70F9-4A3E-A8C4-4C2AFC188EE6Q34516773-8CC8981B-9F89-4323-A560-BE8211B9190EQ37223655-9619BDDC-D93F-463F-AABA-A05264999331Q37395800-62DDBADC-3421-411E-B5E6-95D05A334385Q37696195-60C81771-CEE9-433C-88C0-F0900E1D9D8FQ38616121-6F672D54-A764-4771-AF35-9C2A80DDC785Q38749541-B2C0BBD6-84CF-46FE-82F1-CB54F4304670Q38816145-BDB24022-430D-40A3-8F5A-9E1FDAFC0C82Q39033964-B64048DB-8BDD-48E8-ADEA-B1D17D434C23Q41534994-CDF0AB4D-91D6-4B90-AD86-4E4EED2A611CQ41708842-435B81D1-A040-4EE7-9818-8F32BFD7AE90Q42122613-CBDD992F-7CBF-44F9-88D2-82D457CE0A6DQ49344856-5F22FA02-AA6B-486B-B703-F2C8B96BEF97Q58698678-F418DB53-7C9A-414A-A2E8-A8CF5268DA93
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Arginine deprivation in cancer therapy.
@en
type
label
Arginine deprivation in cancer therapy.
@en
prefLabel
Arginine deprivation in cancer therapy.
@en
P2093
P1476
Arginine deprivation in cancer therapy.
@en
P2093
Lynn G Feun
Macus Tien Kuo
Niramol Savaraj
P356
10.1097/MCO.0000000000000122
P577
2015-01-01T00:00:00Z